E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare the efficacy of Symbicort® Maintenance and Reliever Therapy (SMART) (Symbicort Turbuhaler® 160/4.5μg, one inhalation bid plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation bid plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy by evaluation of time to first asthma exacerbation. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is to investigate safety of Symbicort SMART and of Symbicort 160/4.5 μg, one inhalation bid plus terbutaline Turbuhaler 0.4 mg as needed in terms of adverse events, laboratory variables, morning p-cortisol, 12-lead ECG, pulse rate and blood pressure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of signed and dated informed consent at Visit 1 and prior to any study specific procedures. For patients under-age, signed informed consent from both the patient and the patient’s parent/legal guardian is required.
2. Outpatients of either gender aged ≥16 years at Visit 1
3. Diagnosis of asthma according to GINA 2007 with a documented history of at least 6 months duration prior to Visit 2
4. FEV1 ³ 50% of predicted normal value pre-bronchodilator
5. Reversible airway obstruction (according to a reversibility test performed at Visit 2), defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline (delivered dose) Turbuhaler
6. Prescribed use of inhaled GCS (any brand) for at least 12 weeks prior to Visit 2
7. The daily prescribed dose of inhaled GCS during the last 4 weeks prior to Visit 2 should have been constant and at least 400 μg/day of fluticasone or Qvar, at least 600 μg/day of budesonide, at least 1000 μg/day of any other beclometasone dipropionate (BDP), or equivalent dose of any other inhaled GCS (GINA 2007)
8. A history of at least 1 asthma exacerbation, as defined in Section 3.1, the last 12 months prior to Visit 2
For inclusion in the study treatment period patients must fulfill the following criteria at Visit 3:
9. Use of as-needed medication due to asthma symptoms on at least 5 of the last 7 days of the run-in period, not including the day of Visit 3
10. Capable of using a PEF meter and Turbuhaler and correctly filling in the diary
11. Morning PEF values recorded for at least 8 of the last 10 days of the run-in period (including the value obtained in the morning of Visit 3)
12. Not more than 10 inhalations of as-needed medication on any day of the run-in period
13. The patient must not have had an asthma exacerbation, as defined in Section 3.1, during the run-in period
14. The patient must be eligible for the study in accordance with the exclusion criteria
|
|
E.4 | Principal exclusion criteria |
1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
2. Previous randomization of treatment in the present study
3. Participation in another clinical study during the course of the study or within 4 weeks before Visit 2
4. Known or suspected hypersensitivity to study therapy or excipient
5. Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks prior to Visit 2
6. Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks prior to Visit 2
7. Use of any β-blocking agent, including eye-drops
8. Current or previous smoker with a smoking history of ≥10 pack years
9. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study
10. Any clinically relevant abnormal findings in physical examination, laboratory variables, vital signs or ECG at Visit 2, which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study
11. Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
12. Planned hospitalisation during the study
13. Suspected poor capability, as judged by the investigator, of following instructions of the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first asthma exacerbation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 140 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |